Pathogenesis and Treatment in IgA Nephropathy An International Compa
This book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe
- PDF / 7,688,788 Bytes
- 342 Pages / 439.42 x 683.15 pts Page_size
- 58 Downloads / 188 Views
123
Pathogenesis and Treatment in IgA Nephropathy
ThiS is a FM Blank Page
Yasuhiko Tomino Editor
Pathogenesis and Treatment in IgA Nephropathy An International Comparison
Editor Yasuhiko Tomino Medical Corporation SHOWAKAI Tokyo Japan
ISBN 978-4-431-55587-2 ISBN 978-4-431-55588-9 DOI 10.1007/978-4-431-55588-9
(eBook)
Library of Congress Control Number: 2016933030 © Springer Japan 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Japan KK
Preface
I have studied IgA nephropathy for more than 40 years and have obtained several findings in the fields of pathology, immunology, molecular biology, and experimental pathology—all of which have shed much light on the mechanisms of initiation, development, and progression of this disease. I have also undertaken new treatments for patients and developed animal models for IgA nephropathy. This book discusses the latest findings on the pathogeneses and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and varying treatment strategies in different regions such as Asia, the EU, and the U.S. Nearly 50 years have passed since Dr. Jean Berger first described primary IgA nephropathy (“Nephropathy with mesangial IgA-IgG deposits”) as a new disease entity. Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (polymeric IgA1) and C3 in glomerular mesangial areas with mesangial cell proliferation and the expansion of mesangial matrices. It is clear that IgA nephropathy is one of the most common types of chronic glomerulonephritis in the world. This disease may lead to end-stage kidney disease (ESKD), with its enormous economic impact on healthcare everywhere. Efforts by many investigators around the world have gradually clarified various aspects of the pathogenesis and treatment of IgA nephropathy. It should be note
Data Loading...